BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 31503357)

  • 1. Functional validation of metabolic genes that distinguish Gleason 3 from Gleason 4 prostate cancer foci.
    Roberto D; Selvarajah S; Park PC; Berman D; Venkateswaran V
    Prostate; 2019 Nov; 79(15):1777-1788. PubMed ID: 31503357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene expression relationship between prostate cancer cells of Gleason 3, 4 and normal epithelial cells as revealed by cell type-specific transcriptomes.
    Pascal LE; Vêncio RZ; Page LS; Liebeskind ES; Shadle CP; Troisch P; Marzolf B; True LD; Hood LE; Liu AY
    BMC Cancer; 2009 Dec; 9():452. PubMed ID: 20021671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-regulation of protein kinase, DNA-activated, catalytic polypeptide attenuates tumor progression and is an independent prognostic predictor of survival in prostate cancer.
    Zhang X; Wang Y; Ning Y
    Urol Oncol; 2017 Mar; 35(3):111.e15-111.e23. PubMed ID: 27856181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clonal progression of prostate cancers from Gleason grade 3 to grade 4.
    Sowalsky AG; Ye H; Bubley GJ; Balk SP
    Cancer Res; 2013 Feb; 73(3):1050-5. PubMed ID: 23204237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 12-gene expression signature is associated with aggressive histological in prostate cancer: SEC14L1 and TCEB1 genes are potential markers of progression.
    Agell L; Hernández S; Nonell L; Lorenzo M; Puigdecanet E; de Muga S; Juanpere N; Bermudo R; Fernández PL; Lorente JA; Serrano S; Lloreta J
    Am J Pathol; 2012 Nov; 181(5):1585-94. PubMed ID: 23083832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of HMGA2 inhibits cellular proliferation and invasion, improves cellular apoptosis in prostate cancer.
    Cai J; Shen G; Liu S; Meng Q
    Tumour Biol; 2016 Jan; 37(1):699-707. PubMed ID: 26242267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Silencing TTK expression inhibits the proliferation and progression of prostate cancer.
    Chen S; Wang J; Wang L; Peng H; Xiao L; Li C; Lin D; Yang K
    Exp Cell Res; 2019 Dec; 385(1):111669. PubMed ID: 31605696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced FRG1 expression promotes prostate cancer progression and affects prostate cancer cell migration and invasion.
    Tiwari A; Mukherjee B; Hassan MK; Pattanaik N; Jaiswal AM; Dixit M
    BMC Cancer; 2019 Apr; 19(1):346. PubMed ID: 30975102
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SOCS3 Immunohistochemical Expression Seems to Support the 2005 and 2014 International Society of Urological Pathology (ISUP) Modified Gleason Grading System.
    Pierconti F; Martini M; Cenci T; Petrone GL; Ricci R; Sacco E; Bassi PF; Larocca LM
    Prostate; 2017 May; 77(6):597-603. PubMed ID: 28144985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and Validation of PCAT14 as Prognostic Biomarker in Prostate Cancer.
    Shukla S; Zhang X; Niknafs YS; Xiao L; Mehra R; Cieślik M; Ross A; Schaeffer E; Malik B; Guo S; Freier SM; Bui HH; Siddiqui J; Jing X; Cao X; Dhanasekaran SM; Feng FY; Chinnaiyan AM; Malik R
    Neoplasia; 2016 Aug; 18(8):489-99. PubMed ID: 27566105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Prostate Stromal Transcriptome in Aggressive and Lethal Prostate Cancer.
    Ma C; Zhou Y; Fanelli GN; Stopsack KH; Fiorentino M; Zadra G; Mucci LA; Loda M; Tyekucheva S; Penney KL
    Mol Cancer Res; 2023 Mar; 21(3):253-260. PubMed ID: 36511902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. hsa-miR-135a-1 inhibits prostate cancer cell growth and migration by targeting EGFR.
    Xu B; Tao T; Wang Y; Fang F; Huang Y; Chen S; Zhu W; Chen M
    Tumour Biol; 2016 Oct; 37(10):14141-14151. PubMed ID: 27524492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Validation of a 10-gene molecular signature for predicting biochemical recurrence and clinical metastasis in localized prostate cancer.
    Abou-Ouf H; Alshalalfa M; Takhar M; Erho N; Donnelly B; Davicioni E; Karnes RJ; Bismar TA
    J Cancer Res Clin Oncol; 2018 May; 144(5):883-891. PubMed ID: 29511883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ankyrin G expression is associated with androgen receptor stability, invasiveness, and lethal outcome in prostate cancer patients.
    Wang T; Abou-Ouf H; Hegazy SA; Alshalalfa M; Stoletov K; Lewis J; Donnelly B; Bismar TA
    J Mol Med (Berl); 2016 Dec; 94(12):1411-1422. PubMed ID: 27534968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miRNAs dysregulated in association with Gleason grade regulate extracellular matrix, cytoskeleton and androgen receptor pathways.
    Lichner Z; Ding Q; Samaan S; Saleh C; Nasser A; Al-Haddad S; Samuel JN; Fleshner NE; Stephan C; Jung K; Yousef GM
    J Pathol; 2015 Oct; 237(2):226-37. PubMed ID: 26011734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A molecular correlate to the Gleason grading system for prostate adenocarcinoma.
    True L; Coleman I; Hawley S; Huang CY; Gifford D; Coleman R; Beer TM; Gelmann E; Datta M; Mostaghel E; Knudsen B; Lange P; Vessella R; Lin D; Hood L; Nelson PS
    Proc Natl Acad Sci U S A; 2006 Jul; 103(29):10991-6. PubMed ID: 16829574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Not all gleason pattern 4 prostate cancers are created equal: A study of latent prostatic carcinomas in a cystoprostatectomy and autopsy series.
    Siadat F; Sykes J; Zlotta AR; Aldaoud N; Egawa S; Pushkar D; Kuk C; Bristow RG; Montironi R; van der Kwast T
    Prostate; 2015 Sep; 75(12):1277-84. PubMed ID: 25963383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Signatures of Adverse Pathological Features, Androgen Insensitivity and Metastatic Potential in Prostate Cancer.
    Tolkach Y; Merseburger A; Herrmann T; Kuczyk M; Serth J; Imkamp F
    Anticancer Res; 2015 Oct; 35(10):5443-51. PubMed ID: 26408707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HMGCS2 functions as a tumor suppressor and has a prognostic impact in prostate cancer.
    Wan S; Xi M; Zhao HB; Hua W; Liu YL; Zhou YL; Zhuo YJ; Liu ZZ; Cai ZD; Wan YP; Zhong WD
    Pathol Res Pract; 2019 Aug; 215(8):152464. PubMed ID: 31176575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.